A may be ready soon #vaccine against the#Hiv. The news was given during the latest global conference in Durban against#Aids: in a new study published in the journal retrovirology a group of researchers led by Barbara Ensoli, director of the National AIDS Center (Cnaids) of the Istituto Superiore di Sanità, has in fact demonstrated the vaccine's ability to increase the levels of CD4+ T lymphocytes, the cells of the immune system that are targeted by the virus .
The Made in Italy vaccine was therefore promoted from South Africa which strengthens the drugs against HIV. Other studies had already demonstrated this in the past effectiveness , security of the vaccine. The trial began in South Africa, and involved patients infected with different virus subtypes than those present in Italian participants.
“By administering a very small amount of the Tat protein we were able to induce an immune response capable of improve the effectiveness of anti-HIV drugs, evidenced by a significant increase in CD4 T cells, ”said Ensoli.
The Italian vaccine against HIV targets Tat, a virus protein produced in the early stages of infection; patients' expectations are also increased.
Breakthrough on the HIV vaccine in summary
The news that an HIV vaccine may be ready soon is very exciting. This vaccine, developed in Italy, has already proven to be safe and effective. The testing of this vaccine began in South Africa and involved patients with subtypes of the virus different from those found in the Italian participants. The vaccine targets Tat, a virus protein produced in the early stages of infection.
By administering a very small amount of Tat protein, researchers were able to induce an immune response capable of improving the effectiveness of anti-HIV drugs. This could mean that people infected with HIV will have a better chance of long-term survival. The news that an HIV vaccine may soon be ready is very exciting. This vaccine, developed in Italy, has already proven to be safe and effective. The testing of this vaccine began in South Africa and involved patients with subtypes of the virus different from those found in the Italian participants. The vaccine targets Tat, a virus protein produced in the early stages of infection. By administering a very small amount of Tat protein, researchers were able to induce an immune response capable of improving the effectiveness of anti-HIV drugs. This could mean that people infected with HIV will have a better chance of long-term survival.
